Kim A. Reiss Binder, MD, medical oncologist, assistant program director, Hematology/Oncology Fellowship Program, Abramson Cancer Center, Penn Medicine, assistant professor of medicine, Hospital of the University of Pennsylvania, discusses the initial results of a phase 1 trial (NCT04660929), which is evaluating CT-0508 in patients with HER2-overexpressing solid tumors. 

CT-0508 is a cell product comprised of autologous peripheral blood monocyte–derived macrophages that are transduced with an adenoviral vector containing a HER2-directed CAR and locked into an M1 phenotype. The therapy is being evaluated in an ongoing phase 1 trial in patients with HER2-overexpressing solid tumors.

Initial results of 2 patients treated with CT-0508 were presented during the 2021 SITC Annual Meeting. Regarding safety, 1 patient developed grade 2 cytokine release syndrome (CRS) characterized by fever and hypotension on day 3. The toxicity was resolved on day 4 with acetaminophen (Tylenol), cefepime (Maxipime), and fluids. The other patient, as well as 1 patient who was treated on study but not included in the poster presentation, did not develop CRS with CT-0508.

Although further data are needed to determine whether this therapy is safe, patients treated with CT-0508 are unlikely to develop severe CRS based on the therapy’s mechanism of action, Reiss Binder concludes.

Videos

Kim A. Reiss Binder, MD, discusses the initial results of a phase 1 trial, which is evaluating CT-0508 in patients with HER2-overexpressing solid tumors.  



Dr. Reiss Binder on Initial Results of a Phase 1 Study of CT-0508 in HER2+ Solid Tumors 

Kim A. Reiss Binder, MD, assistant professor of medicine in the Division of Hematology Oncology at the University of Pennsylvania, discusses data on maintenance therapy with rucaparib (Rubraca) in patients with pancreatic cancer.

Early, interim data from a study that examined rucaparib maintenance among patients with platinum-sensitive, advanced 

-mutant pancreatic cancer showed that it was very well tolerated, says Binder. The majority of side effects were grade 1, and there were no dose-limiting toxicities. Though, 1 patient was dose-reduced as a result of grade 2 nausea, says Binder. Encouragingly, no grade 3/4 adverse events were reported in the cohort.

Stable disease was evident, and in some cases long term, says Binder. Moreover, some patients experienced tumor shrinkage; this came as a surprise to investigators, as platinum-based chemotherapy is already suppressive. Thirty-two patients have been enrolled of an expected 42 patients. Investigators will continue to gather data to see if the approach warrants further investigation, says Binder.

Kim A. Reiss Binder, MD

Articles

Dr. Reiss Binder on Initial Results of a Phase 1 Study of CT-0508 in HER2+ Solid Tumors

Dr. Binder on Data Regarding Rucaparib Maintenance in Pancreatic Cancer